# A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

> **NCT06333821** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 460 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** Nimotuzumab
- **DRUG:** Cisplatin
- **RADIATION:** External Beam Radiotherapy (EBRT)
- **RADIATION:** Brachytherapy
- **DRUG:** placebo for Nimotuzumab

## Key facts

- **NCT ID:** NCT06333821
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2030-04-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333821, "A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06333821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*